Background/Aims: Nicotinamide plays a protective role in hypoxia-induced cardiomyocyte dysfunction. However, the underlying molecular mechanisms remain poorly understood. The purpose of this study was to investigate these and the effect of nicotinamide pretreatment on hypoxic cardiomyocytes. Methods: Cultured rat cardiomyocytes were pretreated with nicotinamide, subjected to hypoxia for 6 h, and then cell necrosis and apoptosis were examined. The effects of nicotinamide pretreatment on hypoxia-induced reactive oxygen species (ROS) formation, antioxidant enzyme expression, nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+) levels, adenosine triphosphate (ATP) production and mitochondrial membrane potential were tested to elucidate the underlying mechanisms. Results: Based on the findings that nicotinamide treatment decreased protein expression of receptor-interacting protein (RIP; a marker for cell necrosis) and cleaved caspase-3 (CC3; a marker for cell apoptosis) in normoxic cardiomyocytes, we found that it dramatically reduced hypoxia-induced necrosis and apoptosis in cardiomyocytes. The underlying mechanisms of these effects are associated with the fact that it increased protein expression of superoxide dismutase and catalase, increased intracellular levels of NAD+ and ATP concentration, decreased mitochondrial ROS generation and prevented the loss of mitochondrial membrane potential. Conclusion: All of these results indicate that nicotinamide pretreatment protects cardiomyocytes by improving mitochondrial stress. Our study provides a new clue for the utilization of nicotinamide in therapies for ischemic heart disease.

Keywords:
Nicotinamide, Cardioprotection, Mitochondrial stress
1.
Shah DJ, Kim HW, Kim RJ: Evaluation of ischemic heart disease. Heart Fail Clin 2009;5:315–332, v.
2.
Karamitsos TD, Dall’Armellina E, Choudhury RP, Neubauer S: Ischemic heart disease: comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J 2011;162:16–30.
3.
Cadenas S, Aragones J, Landazuri MO: Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease. Cardiovasc Res 2010;88:219–228.
4.
Tompkins AJ, Burwell LS, Digerness SB, Zaragoza C, Holman WL, Brookes PS: Mitochondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. Biochim Biophys Acta 2006;1762:223–231.
5.
Di Lisa F, Bernardi P: Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 2006;70:191–199.
6.
Khan S, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RC: Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 2006;41:256–264.
7.
Di Napoli P, Di Giovanni P, Gaeta MA, D’Apolito G, Barsotti A: Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007;154:602 e601–e605.
8.
Hoane MR, Tan AA, Pierce JL, Anderson GD, Smith DC: Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat. J Neurotrauma 2006;23:1535–1548.
9.
Mokudai T, Ayoub IA, Sakakibara Y, Lee EJ, Ogilvy CS, Maynard KI: Delayed treatment with nicotinamide (vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. Stroke 2000;31:1679–1685.
10.
Hoane MR, Gilbert DR, Holland MA, Pierce JL: Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain. Neurosci Lett 2006;408:35–39.
11.
Sukhodub A, Du Q, Jovanovic S, Jovanovic A: Nicotinamide-rich diet protects the heart against ischaemia-reperfusion in mice: a crucial role for cardiac SUR2A. Pharmacol Res 2010;61:564–570.
12.
Simpson P, Savion S: Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 1982;50:101–116.
13.
Das A, Xi L, Kukreja RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005;280:12944–12955.
14.
Rusanen H, Majamaa K, Hassinen IE: Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A→G mutation in mitochondrial DNA. Biochim Biophys Acta 2000;1500:10–16.
15.
Loos B, Genade S, Ellis B, Lochner A, Engelbrecht AM: At the core of survival: autophagy delays the onset of both apoptotic and necrotic cell death in a model of ischemic cell injury. Exp Cell Res 2011;317:1437–1453.
16.
Xiang F, Huang YS, Zhang DX, Chu ZG, Zhang JP, Zhang Q: Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes. Clin Exp Pharmacol Physiol 2010;37:343–349.
17.
Xiang F, Huang YS, Shi XH, Zhang Q: Mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. FEBS J 2010;277:1929–1938.
18.
Kim YH, Hwang JH, Noh JR, Gang GT, Tadi S, Yim YH, Jeoung NH, Kwak TH, Lee SH, Kweon GR, Kim JM, Shong M, Lee IK, Lee CH: Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase. Free Radic Biol Med 2012;52:880–888.
19.
Trichonas G, Murakami Y, Thanos A, Morizane Y, Kayama M, Debouck CM, Hisatomi T, Miller JW, Vavvas DG: Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci USA 2010;107:21695–21700.
20.
Galluzzi L, Kepp O, Kroemer G: Rip kinases initiate programmed necrosis. J Mol Cell Biol 2009;1:8–10.
21.
Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P: Rip1, a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ 2007;14:400–410.
22.
Lawen A: Apoptosis – an introduction. Bioessays 2003;25:888–896.
23.
Liu CM, Ma JQ, Sun YZ: Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol 2012;258:330–342.
24.
Geiger J, Zou AP, Campbell WB, Li PL: Inhibition of CADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension 2000;35:397–402.
25.
Gul R, Kim SY, Park KH, Kim BJ, Kim SJ, Im MJ, Kim UH: A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H77–H88.
26.
Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, Monks TJ: EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ros-induced renal cell death. Am J Physiol Renal Physiol 2004;287:F1049–F1058.
27.
Woo DK, Shadel GS: Mitochondrial stress signals revise an old aging theory. Cell 2011;144:11–12.
28.
Durieux J, Wolff S, Dillin A: The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011;144:79–91.
29.
Yao H, Sadanaga-Akiyoshi F, Ibayashi S, Iida M: Nicotinamide attenuates focal ischemic brain injury: meta-analysis or mechanism of protection. Stroke 2004;35:2757–2758.
30.
Sadanaga-Akiyoshi F, Yao H, Tanuma S, Nakahara T, Hong JS, Ibayashi S, Uchimura H, Fujishima M: Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra. Neurochem Res 2003;28:1227–1234.
31.
Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z: A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 2005;170:349–355.
32.
Petrosillo G, Di Venosa N, Moro N, Colantuono G, Paradies V, Tiravanti E, Federici A, Ruggiero FM, Paradies G: In vivo hyperoxic preconditioning protects against rat-heart ischemia/reperfusion injury by inhibiting mitochondrial permeability transition pore opening and cytochrome c release. Free Radic Biol Med 2011;50:477–483.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.